826 related articles for article (PubMed ID: 14677084)
21. Treatments for late-life bipolar disorder.
Aziz R; Lorberg B; Tampi RR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):347-64. PubMed ID: 17296540
[TBL] [Abstract][Full Text] [Related]
22. Long-term naturalistic follow-up of lithium augmentation: relevance to bipolarity.
Inoue T; Abekawa T; Nakagawa S; Suzuki K; Tanaka T; Kitaichi Y; Boku S; Nakato Y; Toda H; Koyama T
J Affect Disord; 2011 Mar; 129(1-3):64-7. PubMed ID: 20837361
[TBL] [Abstract][Full Text] [Related]
23. [The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].
Ströhle A
Nervenarzt; 2003 Mar; 74(3):279-91; quiz 292. PubMed ID: 12627245
[TBL] [Abstract][Full Text] [Related]
24. Use of atypical antipsychotics in refractory depression and anxiety.
Nemeroff CB
J Clin Psychiatry; 2005; 66 Suppl 8():13-21. PubMed ID: 16336032
[TBL] [Abstract][Full Text] [Related]
25. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
[TBL] [Abstract][Full Text] [Related]
26. [Limbic-hypothalamic-pituitary-adrenal axis in depression: literature review].
Twardowska K; Rybakowski J
Psychiatr Pol; 1996; 30(5):741-55. PubMed ID: 8984515
[TBL] [Abstract][Full Text] [Related]
27. Lithium addition in antidepressant-resistant depression: effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration.
Birkenhäger TK; van den Broek WW; Fekkes D; Mulder PG; Moleman P; Bruijn JA
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1084-8. PubMed ID: 17467132
[TBL] [Abstract][Full Text] [Related]
28. [Changes in the hypothalamo-pituitary-adrenal axis and the metabolism of serotonin in affective disorders. Therapeutic use of serotonin precursors (review)].
Pérez de los Cobos Peris J
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1986; 14(3):147-274. PubMed ID: 3526823
[No Abstract] [Full Text] [Related]
29. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker?
Ising M; Horstmann S; Kloiber S; Lucae S; Binder EB; Kern N; Künzel HE; Pfennig A; Uhr M; Holsboer F
Biol Psychiatry; 2007 Jul; 62(1):47-54. PubMed ID: 17123470
[TBL] [Abstract][Full Text] [Related]
30. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium.
Dorée JP; Des Rosiers J; Lew V; Gendron A; Elie R; Stip E; Tourjman SV
Curr Med Res Opin; 2007 Feb; 23(2):333-41. PubMed ID: 17288688
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression.
Owashi T; Otsubo T; Oshima A; Nakagome K; Higuchi T; Kamijima K
Psychoneuroendocrinology; 2008 Feb; 33(2):152-61. PubMed ID: 18068306
[TBL] [Abstract][Full Text] [Related]
32. Changes in the hypothalamic-pituitary-adrenal axis and leptin levels during antidepressant treatment.
Himmerich H; Zimmermann P; Ising M; Kloiber S; Lucae S; Kunzel HE; Binder EB; Holsboer F; Uhr M
Neuropsychobiology; 2007; 55(1):28-35. PubMed ID: 17556850
[TBL] [Abstract][Full Text] [Related]
33. Augmentation strategies for treatment-resistant depression: a literature review.
Carvalho AF; Cavalcante JL; Castelo MS; Lima MC
J Clin Pharm Ther; 2007 Oct; 32(5):415-28. PubMed ID: 17875106
[TBL] [Abstract][Full Text] [Related]
34. Low dosage lithium augmentation in venlafaxine resistant depression: an open-label study.
Alevizos B; Alevizos E; Leonardou A; Zervas I
Psychiatriki; 2012; 23(2):143-8. PubMed ID: 22796912
[TBL] [Abstract][Full Text] [Related]
35. Use of endocrine hormones for treating depression.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 Dec; 48(12):13-6. PubMed ID: 21117521
[TBL] [Abstract][Full Text] [Related]
36. Olanzapine: new indication. Prevention of bipolar disorder: unconvincing trials.
Prescrire Int; 2005 Aug; 14(78):140-2. PubMed ID: 16106596
[TBL] [Abstract][Full Text] [Related]
37. [Antidepressive agents in the elderly].
de Hooge JK
Tijdschr Gerontol Geriatr; 1990 Dec; 21(6):259-67. PubMed ID: 1980385
[TBL] [Abstract][Full Text] [Related]
38. Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression.
Bschor T; Baethge C; Adli M; Lewitzka U; Eichmann U; Bauer M
J Psychiatry Neurosci; 2003 May; 28(3):210-6. PubMed ID: 12790161
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project.
Hennings JM; Owashi T; Binder EB; Horstmann S; Menke A; Kloiber S; Dose T; Wollweber B; Spieler D; Messer T; Lutz R; Künzel H; Bierner T; Pollmächer T; Pfister H; Nickel T; Sonntag A; Uhr M; Ising M; Holsboer F; Lucae S
J Psychiatr Res; 2009 Jan; 43(3):215-29. PubMed ID: 18586274
[TBL] [Abstract][Full Text] [Related]
40. Lithium treatment of depression.
Noyes R; Dempsey GM
Dis Nerv Syst; 1974 Dec; 35(12):573-6. PubMed ID: 17896758
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
